doxorubicin + veliparib

The combination of doxorubicin and veliparib represents a therapeutic approach that combines a traditional chemotherapeutic agent (doxorubicin) with a PARP inhibitor (veliparib). This combination has been studied primarily in clinical trials for various cancers, particularly breast and ovarian cancers. Veliparib (ABT-888) is a potent, oral inhibitor of PARP-1 and PARP-2 enzymes, which play crucial roles in DNA damage recognition and repair. By inhibiting these enzymes, veliparib enhances the effects of DNA-damaging agents like doxorubicin. This combination leverages the DNA-damaging effects of doxorubicin with the PARP inhibition of veliparib, which blocks DNA repair mechanisms, potentially enhancing antitumor activity particularly in BRCA-deficient cancers.

Other names

pegylated liposomal doxorubicin + veliparibPLD + veliparib